Gershon, A, Takahashi, M, Seward, J. Varicella vaccine. In: Plotkin, SA, Orenstein, W, Offit, P, eds.
. Pennsylvania: Saunders Company, 2004, pp. 783–823.
Hope-Simpson, RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proceedings of the Royal Society of Medicine
1965; 58: 9–20.
Annemans, L, et al.
Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. Journal of Medical Economics
2010; 13: 537–551.
Arvin, AM, Koropchak, CM, Wittek, AE. Immunological evidence of reinfection with varicella-zoster virus. Journal of Infectious Diseases
1983; 148: 200–205.
Ogunjimi, B, et al.
Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunology
2011; 24: 151–157.
Vossen, MTM, et al.
Development of virus-specific CD4(+) T cells on reexposure to varicella-zoster virus. Journal of Infectious Diseases
2004; 190: 72–82.
Jumaan, AO, et al.
Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. Journal of Infectious Diseases
2005; 191: 2002–2007.
Leung, J, et al.
Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clinical Infectious Diseases
2011; 52: 332–340.
Nelson, MR, Britt, HC, Harrison, CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Medical Journal of Australia
2010; 193: 110–113.
Yih, WK, et al.
The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health
2005; 5: 68.
Brisson, M, et al.
Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine
2002; 20: 2500–2507.
Gershon, AA, et al.
The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. Journal of Infectious Diseases
1996; 173: 450–453.
Thomas, SL, Wheeler, JG, Hall, AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet
2002; 360: 678–682.
Bilcke, J, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Brussels: Belgian Health Care Knowledge Centre (KCE), 2011.
van Hoek, AJ, et al.
Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine
2011; 29: 2411–2420.
Brisson, M, Edmunds, WJ. Varicella vaccination in England and Wales: cost-utility analysis. Archives of Disease in Childhood
2003; 88: 862–869.
Van Casteren, V, Bossuyt, N.Survey site visit Belgium 15 July 2002. Belgian Sentinel Network of General Practitioners, 2002.
Vrijens, F, et al. Nosocomial infections in Belgium, part 2: impact on mortality and costs. Brussels: Belgian Health Care Knowledge Centre (KCE), 2009.
Oxman, MN, et al.
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine
2005; 352: 2271–2284.
Coplan, PM, et al.
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain
2004; 5: 344–356.
Brisson, M, Edmunds, WJ. Epidemiology of varicella-zoster virus in England and Wales. Journal of Medical Virology
2003; 70 (Suppl. 1): S9–14.
Coplan, P, et al.
Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatric Infectious Disease Journal
2001; 20: 641–645.
Brisson, M, et al.
Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiology and Infection
2001; 127: 305–314.
Smith, KJ, Roberts, MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. American Journal of Medicine
2000; 108: 723–729.
Sackett, DL, Torrance, GW. The utility of different health states as perceived by the general public. Journal of Chronic Diseases
1978; 31: 697–704.
Merrett, P, et al.
Strategies to prevent varicella among newly arrived adult immigrants and refugees: A cost-effectiveness analysis. Clinical Infectious Diseases
2007; 44: 1040–1048.
Drolet, M, et al.
A prospective study of the herpes zoster severity of illness. Clinical Journal of Pain
2010; 26: 656–666.
Scott, FT, et al.
The burden of herpes zoster: a prospective population based study. Vaccine
2006; 24: 1308–1314.
Opstelten, W, et al.
Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain
2007; 132 (Suppl. 1): S52–9.
Drolet, M, et al.
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Canadian Medical Association Journal
2010; 182: 1731–1736.
Yawn, BP, et al.
Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings
2011; 86: 88–93.
Wareham, DW, Breuer, J. Herpes zoster. British Medical Journal
2007; 334: 1211–1215.
Wootton, SH, et al.
The epidemiology of children hospitalized with herpes zoster in Canada: Immunization Monitoring Program, Active (IMPACT), 1991–2005. Pediatric Infectious Disease Journal
2008; 27: 112–118.
Insinga, RP, IItzler, RF, Pellissier, JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics
2007; 25: 155–169.
White, RR, et al.
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics
2009; 27: 781–792.